dabigatran etexilate mesilate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
dabigatran etexilate mesilate: clinical details
Prescribing considerations
- Confirm the licensed indication, age-appropriate formulation, renal function, bleeding risk, concurrent medicines and ability to use the formulation correctly.
- Exposure is strongly influenced by renal function and P-glycoprotein interactions.
- Review before surgery, invasive procedures or neuraxial interventions; interruption must be individualised to renal function, bleeding risk and urgency.
- Plan transitions carefully when stopping or switching anticoagulants.
- Idarucizumab provides specific rapid reversal in adults when clinically required; paediatric efficacy and safety are not established.
Contraindications and cautions
- Active clinically significant bleeding or a lesion or condition carrying a major bleeding risk
- Severe renal impairment in adults, defined by creatinine clearance below 30 mL/min
- Paediatric eGFR below 50 mL/min/1.73 m²
- Concomitant anticoagulation except in specified switching, catheter or specialist circumstances
- Hepatic impairment or disease expected to affect survival
- Systemic ketoconazole, itraconazole, ciclosporin, dronedarone or glecaprevir/pibrentasvir
- Prosthetic heart valves requiring anticoagulation
- Hypersensitivity to the active substance or an excipient
Monitoring
- Before treatment: full blood count, liver function, renal profile, body weight and baseline clotting screen.
- Use Cockcroft–Gault creatinine clearance for adult prescribing; eGFR may overestimate renal function.
- Review adherence, bleeding, anaemia, thromboembolic symptoms, interactions and modifiable bleeding risks; repeat blood count, liver and renal tests periodically.
- Monitor more often with older age, frailty, renal impairment, interacting medicines, dehydration or intercurrent illness.
- Routine INR monitoring is inappropriate; specialist coagulation assays may help in selected emergencies or peri-procedural situations.
Clinical pharmacology
An orally absorbed prodrug converted by esterases to dabigatran, a competitive, reversible direct inhibitor of free and fibrin-bound thrombin. Dabigatran is not metabolised through CYP450 and is eliminated predominantly by the kidneys.
Formulation and product differences
- Hard capsules must be swallowed intact; opening them increases bioavailability and bleeding risk.
- Coated granules are intended for children able to swallow soft food and require age- and weight-specific prescribing.
- Granules must be mixed with specified soft food or apple juice, used promptly, kept away from milk products and not given through feeding tubes.
- Formulations are not directly interchangeable without reassessing the prescription.
dabigatran etexilate mesilate preparations and strengths
Capsule
Route: Oral
Strengths: 75 mg, 110 mg, 150 mg
Granules
Route: Oral
Strengths: 20 mg, 30 mg, 40 mg, 50 mg, 110 mg, 150 mg
dabigatran etexilate mesilate interactions
Check prescription, over-the-counter and herbal products before starting or stopping them. Important examples include:
Other anticoagulants
Usually cause an unacceptable bleeding risk when combined, except during carefully managed switching or specified specialist use.
Aspirin, clopidogrel and other antiplatelets
Can substantially increase bleeding risk.
NSAIDs such as ibuprofen or naproxen
Can increase gastrointestinal and other bleeding, particularly with ongoing use.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.